Berenberg Bank Reiterates "Hold" Rating for GSK (LON:GSK)

GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating reissued by equities researchers at Berenberg Bank in a research note issued to investors on Friday,Digital Look reports. They currently have a GBX 1,600 ($21.49) price objective on the stock. Berenberg Bank's price objective would suggest a potential upside of 18.21% from the stock's current price.

GSK has been the topic of several other reports. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a GBX 1,450 ($19.47) target price on shares of GSK in a research report on Tuesday, July 8th. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Friday. Finally, Shore Capital reissued a "buy" rating on shares of GSK in a report on Wednesday, April 30th.

GSK Stock Performance

Shares of GSK stock traded down GBX 59.50 ($0.80) during trading on Friday, hitting GBX 1,353.50 ($18.18). 392,537,375 shares of the company's stock traded hands, compared to its average volume of 16,499,305. GSK has a 1 year low of GBX 1,242.50 ($16.68) and a 1 year high of GBX 1,678.68 ($22.54). The business has a 50-day simple moving average of GBX 1,435.91 and a 200-day simple moving average of GBX 1,422.12. The stock has a market capitalization of £54.92 billion, a P/E ratio of 21.86, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds purchased 1,350 shares of the firm's stock in a transaction on Friday, June 20th. The shares were acquired at an average cost of GBX 1,435 ($19.27) per share, with a total value of £19,372.50 ($26,013.83). Also, insider Wendy Becker acquired 545 shares of the company's stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of GBX 1,435 ($19.27) per share, with a total value of £7,820.75 ($10,501.88). In the last quarter, insiders bought 1,905 shares of company stock valued at $2,732,835. Company insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.